Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.57 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13159656 | 1.00 | HDAC1 (1.00) | HDAC1HDAC4MEF2DPABPC1HDAC6 | |
| SCHEMBL13928109 | 0.92 | HDAC1 (0.85) | HDAC1HDAC4MEF2DHDAC6HDAC3 | |
| SCHEMBL8311632 | 0.92 | HDAC1 (0.85) | HDAC1HDAC4MEF2DHDAC6HDAC3 | |
| SCHEMBL3427205 | 0.92 | HDAC1 (0.84) | HDAC1HDAC4MEF2DPABPC1HDAC6 | |
| SCHEMBL13159689 | 0.88 | HDAC1 (0.80) | HDAC1HDAC4MEF2DHDAC6HDAC3 | |
| SCHEMBL13928110 | 0.88 | HDAC1 (1.00) | HDAC1HDAC4MEF2DHDAC6HDAC3 | |
| SCHEMBL8312518 | 0.88 | HDAC1 (1.00) | HDAC1HDAC4MEF2DHDAC6HDAC3 | |
| SCHEMBL8094598 | 0.87 | HDAC1 (0.76) | HDAC1HDAC4PABPC1HDAC6HDAC3 | |
| SCHEMBL13159659 | 0.86 | HDAC1 (1.00) | HDAC1HDAC4MEF2DHDAC6HDAC3 | |
| SCHEMBL8344769 | 0.86 | HDAC1 (1.00) | HDAC1HDAC4MEF2DHDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054720-A1 | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
| US-20090054720-A1 | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054720-A1 | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC4 4/4885MEF2D 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.